[{"orgOrder":0,"company":"Kenox Pharmaceuticals","sponsor":"Lactiga","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Collaboration","leadProduct":"LCTG-001","moa":"Undisclosed","graph1":"Immunology","graph2":"Preclinical","graph3":"Kenox Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Kenox Pharmaceuticals \/ Lactiga","highestDevelopmentStatusID":"4","companyTruncated":"Kenox Pharmaceuticals \/ Lactiga"}]

Find Clinical Drug Pipeline Developments & Deals by Kenox Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : The collaboration will leverage Kenox extensive expertise in nasal and inhaled pharmaceutical development of LCTG-001. It is being evaluated for mucosal-targeted Secretory IgA.

                          Product Name : LCTG-001

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          March 10, 2025

                          Lead Product(s) : LCTG-001

                          Therapeutic Area : Immunology

                          Highest Development Status : Preclinical

                          Sponsor : Lactiga

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank